MARKETS / NYSE / TDOC
NYSE · SERVICES-OFFICES & CLINICS OF DOCTORS OF MEDICINE · LARGE CAP

Teladoc Health, Inc. TDOC

13 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$2.5B
▼ 1.5% vs FY2024
EPS · FY25
$-1.14
Dividend / sh · FY25
Payout · FY25
ROE · FY25
-13.9%
Net margin · FY25
-7.9%
Dividend coverage
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 2.5B
Revenue, FY2025 · full 13-year series below
Revenue Net income
0.81.62.43.22.5-0.220132016201920222025
0.81.62.43.22.5-0.22016201920222025

The company lost 8 cents on every revenue dollar this year.

Per share
USD -1.14
Diluted EPS, FY2025
EPS
0.40.81.2-1.1420132016201920222025
0.40.81.2-1.142016201920222025

The company pays no cash dividend.

Profitability
-13.9%
Return on equity, FY2025
ROE
0.250.50.751-13.9%20132016201920222025
0.250.50.751-13.9%2016201920222025
Operating margin-10.4%
Net margin-7.9%
Return on assets-6.3%

Each USD of equity lost 14 cents this year.

Returned to shareholders
returned in FY2025 · dividends + net buybacks
Dividends paid
Net buybacks
Share of profit
Consecutive raises

Growth
+18.3% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
+1.7%
+18.3%
+41.7%

Compound annual rates per period — left blank where the series crosses a loss.

Share base
0.18B
Shares outstanding, FY2025
0.000.1820132016201920222025
0.050.182016201920222025
Change, 5 years+18.7%
Change, 10 years

The share count grew 19% in five years — the same company, cut into more, smaller slices.

Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 2.9B
total assets, end of FY2025
Total assetsUSD 2.9B
EquityUSD 1.4B
CashUSD 781.1M
Current ratio2.77×

Equity funds 48% of total assets.

History
13 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
Revenue $B
2.5
2.6
2.6
2.4
2.0
1.1
0.6
0.4
0.2
0.1
0.1
0.0
0.0
Operating income $B
−0.3
−1.0
−0.2
−13.7
−0.3
−0.5
−0.1
−0.1
−0.1
−0.1
−0.1
−0.0
−0.0
EBITDA $B
·
·
·
−13.4
−0.1
−0.4
−0.0
−0.0
−0.1
−0.1
−0.1
−0.0
−0.0
Income tax $B
−0.0
0.0
0.0
−0.0
0.0
−0.1
−0.0
0.0
−0.0
0.0
0.0
0.0
0.0
Net income $B
−0.2
−1.0
−0.2
−13.7
−0.4
−0.5
−0.1
−0.1
−0.1
−0.1
−0.1
−0.0
−0.0
EPS, diluted $
−1.14
−5.87
−1.34
−84.60
−2.73
−5.36
−1.38
−1.47
−1.93
−1.75
−2.91
−10.25
−8.05
Dividend / sh $
·
·
·
·
·
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
·
·
·
·
·
·
ROE %
−13.9
−52.5
−9.5
−148.8
−2.7
−5.7
−9.8
−12.4
−27.0
−36.3
−104.5
·
·
Shares out B
0.18
0.17
0.17
0.16
0.16
0.15
0.07
0.07
0.06
0.05
0.04
0.00
·

Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.

How we verifyAUDITED
43 of 43
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity

Every figure was compared against the original statement: 0 failures and 0 presentation gaps.

What we don’t show

We’d rather say what’s missing than fill the gap with an estimate.

P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed